Hypofibrinogenemia Induced by Eravacycline: A Rare but Serious Adverse Effect of a Novel Antimicrobial Agent

Cureus 2026 Open access

Read full text
Authors: Pradeep Khanal, Suhail Sapkota, Ioannis Karageorgiou, Tareq Al Baghdadi
DOI: 10.7759/cureus.107424
Cited by: 1
References: 10

Abstract

Eravacycline is a broad-spectrum third-generation tetracycline, notably effective against multidrug-resistant organisms. Emerging evidence suggests an association with hypofibrinogenemia, though clinical recognition remains limited. We report a case of an 84-year-old male patient who presented with hypofibrinogenemia (fibrinogen

Fields of Study & Subjects

Blood properties and coagulation Heparin-Induced Thrombocytopenia and Thrombosis Platelet Disorders and Treatments

Publication details

Journal / source
Cureus
Publisher
Springer Science and Business Media LLC
Volume
18
Issue
4
Pages
e107424–e107424
Publication date
20 April 2026
Language
EN